scholarly journals Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1

2018 ◽  
Vol 8 (4) ◽  
pp. 283-291 ◽  
Author(s):  
Jennifer L. Griffith ◽  
Stephanie M. Morris ◽  
Jasia Mahdi ◽  
Manu S. Goyal ◽  
Tamara Hershey ◽  
...  

BackgroundWe sought to define the radiologic features that differentiate neoplastic from non-neoplastic T2 hyperintensities (T2Hs) in neurofibromatosis type 1 (NF1) and identify those lesions most likely to require oncologic surveillance.MethodsWe conducted a single-center retrospective review of all available brain MRIs from 68 children with NF1 (n = 190) and 46 healthy pediatric controls (n = 104). All T2Hs identified on MRI were characterized based on location, border, shape, degree of T1 hypointensity, and presence of mass effect or contrast enhancement, and subsequently classified using newly established radiologic criteria as either unidentified bright objects (UBOs) or probable tumors. Lesion classification was pathologically confirmed in 10 NF1 cases.ResultsT2Hs were a highly sensitive (94.4%; 95% confidence interval [CI] 86.4%–98.5%) and specific (100.0%; 95% CI 92.3%–100.0%) marker for the diagnosis of NF1. UBOs constituted the majority of T2Hs (82%) and were most frequently located in cerebellar white matter, medial temporal lobe, and thalamus, where they were more likely than probable tumors to be bilateral (p < 0.001) and have nondiscrete borders (p < 0.001). Surprisingly, 57% of children with T2Hs harbored lesions classified as probable tumors, and 28% of children with probable tumors received treatment. In contrast to UBOs, probable tumors were most frequently located within the globus pallidus and medulla, and rarely occurred prior to 3 years of age.ConclusionsWith the implementation of standardized radiologic criteria, a high prevalence of brain tumors was identified in this at-risk population of children, of which nearly one-third required treatment, emphasizing the need for appropriate oncologic surveillance for patients with NF1 harboring nonoptic pathway brain tumors.

2016 ◽  
Vol 31 (14) ◽  
pp. 1540-1545 ◽  
Author(s):  
Stephanie M. Morris ◽  
Courtney L. Monroe ◽  
David H. Gutmann

Neurofibromatosis type 1 is a common neurogenetic disorder characterized by significant clinical variability. As such, numerous studies have focused on identifying clinical, radiographic, or molecular biomarkers that predict the occurrence or progression of specific clinical features in individuals with neurofibromatosis type 1. One of these clinical biomarkers, macrocephaly, has been proposed as a prognostic factor for optic pathway glioma development. In the current study, the authors demonstrate that macrocephaly is not associated with the development of these brain tumors or the need to institute treatment for clinical progression. These findings suggest that macrocephaly is not a robust biomarker of optic pathway glioma formation or progression in children with neurofibromatosis type 1.


2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Alessandra D’Amico ◽  
Federica Mazio ◽  
Lorenzo Ugga ◽  
Renato Cuocolo ◽  
Mario Cirillo ◽  
...  

2008 ◽  
Vol 38 (3) ◽  
pp. 305-310 ◽  
Author(s):  
José Roberto Lopes Ferraz Filho ◽  
Marcos Pontes Munis ◽  
Antonio Soares Souza ◽  
Rafael Angelo Sanches ◽  
Eni Maria Goloni-Bertollo ◽  
...  

2005 ◽  
Vol 27 (8) ◽  
pp. 595-597 ◽  
Author(s):  
Atsushi Imamura ◽  
Naoki Matsuo ◽  
Miho Okuda ◽  
Hideyuki Morita ◽  
Masako Iwata ◽  
...  

2013 ◽  
Vol 49 (1) ◽  
pp. 55-59 ◽  
Author(s):  
Shawn L. Hervey-Jumper ◽  
Nirmish Singla ◽  
Stephen S. Gebarski ◽  
Patricia Robertson ◽  
Cormac O. Maher

2007 ◽  
Vol 23 (5) ◽  
pp. E2 ◽  
Author(s):  
Mandy J. Binning ◽  
James K. Liu ◽  
John R. W. Kestle ◽  
Douglas L. Brockmeyer ◽  
Marion L. Walker

✓Optic pathway gliomas represent approximately 3–5% of childhood intracranial tumors. They usually occur in children during the first decade of life and are seen in 11–30% of patients with neurofibromatosis Type 1 (NF1). Although these tumors are typically low-grade gliomas, the clinical course and natural history are highly variable, making treatment paradigms difficult. Overall, however, they are often indolent tumors that can be observed over time for progression without initial treatment, especially in patients with NF1. Chemotherapy is the first-line treatment for progressive tumors, and radiation therapy is reserved for patients with progressive disease who are older than 5–7 years. Surgery is reserved for large tumors causing mass effect or hydrocephalus and tumors confined to the orbit or unilateral optic nerve.


Sign in / Sign up

Export Citation Format

Share Document